Zhejiang Sunflower subsidiary updates drug manufacturing license, expanding production

Zhejiang Sunflower Great Health Technology Co., Ltd. announced that its subsidiary, Zhejiang Betard Pharmaceutical Co., Ltd., obtained a renewed "Drug Manufacturing License" from the Zhejiang Provincial Medical Products Administration. This update signifies an approval for changes in the scope of their manufacturing activities.

The revised license includes updates to Betard Pharmaceutical's self-produced drug scope, specifically adding GMP compliance inspection numbers and inspection scopes. For contract manufacturing, changes were made regarding the entrusted product "Dopasine Tablets" from Guangdong Wecare Pharmaceutical Co., Ltd., including modifications to the delegating party's registered address, product specifications, and the addition of GMP compliance inspection numbers, inspection scopes, approval numbers, and their validity periods.

The license, valid until August 11, 2030, covers the production of lyophilized powder injections, active pharmaceutical ingredients, tablets, and hard capsules at its facility in the Industrial Zone, Sanjiang Road, Yuecheng District, Shaoxing City, Zhejiang Province. This strategic adjustment aims to meet market demand, with the company stating no significant impact on its performance.